lURIE CANCER CENTER AND Northwestern Medicine
EXPERTS TO PRESENT AT THE 2025 ASCO® Annual Meeting
Physicians and scientists from the Robert H. Lurie Comprehensive Cancer Center of Northwestern University and Northwestern Medicine will present and discuss leading-edge research in cancer care at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, May 30 – June 3, at McCormick Place in Chicago and Online. Visit us at Booth 11016.
The program features more than 200 sessions complementing the meeting’s theme: Driving Knowledge to Action: Building a Better Future. Below are some highlights from this year’s presentations.
The program features more than 200 sessions complementing the meeting’s theme: Driving Knowledge to Action: Building a Better Future. Below are some highlights from this year’s presentations.
a sample of our presentation schedule
Saturday, May 31
|
Time
|
Location
|
Track & Session
|
Presenter
|
Learn More
|
|
8:00 AM
|
S504
|
Central Nervous System Tumors
Case-Based Panel: Therapeutic Options for Patients With Leptomeningeal Disease |
|
9:00 AM
|
Hall A
|
Sarcoma
Poster Session: Clinical and prognostic implications of the TCR repertoire in leiomyosarcoma |
|
9:00 AM
|
Hall A
|
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Poster Session: EMERALD-Y90: A phase 2 study to evaluate transarterial radioembolization (TARE) followed by durvalumab (D) and bevacizumab (B) for the treatment of participants (pts) with unresectable hepatocellular carcinoma (uHCC) eligible for embolization |
|
9:00 AM
|
Hall A
|
Gastrointestinal Cancer – Colorectal and Anal
Poster Session: Leveraging EHRs and a phenome-wide association study to identify pre-diagnostic clinical markers in early-onset colorectal cancer |
|
9:00 AM
|
Hall A
|
Central Nervous System Center Tumors
Poster Session: Combining abemaciclib, temozolomide, and radiation in DIPG PDOX models: Insights from single-cell RNA-seq on cellular subtypes and genes critical for responsiveness and resistance |
|
Breast Cancer - Metastatic
Oral Abstract Session: New at the Dispensary: Easy Pills to Swallow? |
|
1:30 PM
|
Hall A
|
Quality Care/Health Services Research
Poster Session: Longitudinal risk of physical functional impairment and health care utilization in cancer survivors within 3 years of diagnosis |
|
1:30 PM
|
Hall A
|
Quality Care/Health Services Research
Poster Session: Utilization and timeliness of next-generation sequencing testing for patients with resected or metastatic non-small cell lung cancer: A real-world analysis |
|
3:30 PM
|
Hall A
|
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Oral Abstract Session: Preliminary results from the randomized phase 2 study (1801 part 3B) of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) versus GnP alone in patients (pts) with previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC) |
Devalingam Mahalingam, MD, PhD
Abstract: 4006 |
Sunday, June 1
|
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia
Highlights of the Day Session |
|
8:00 AM
|
Hall B1
|
Breast Cancer - Local/Regional/Adjuvant
Rapid Oral Abstract Session: The Promise study: A presurgical randomized clinical trial of CE/BZA vs placebo in postmenopausal women with ductal carcinoma in situ |
|
8:00 AM
|
E451
|
Liver-Directed Therapies in Colorectal Cancer: Old Hats and New Tricks
Education Session: Ablation, Embolization, and Radiation Approaches to Colorectal Liver Metastases |
|
9:00 AM
|
Hall A
|
Hematologic Malignancies: Lymphoma and Chronic Lymphocytic Leukemia
Poster Session: Comparative analysis of survival outcomes in infused versus not-infused patients with aggressive B-cell lymphoma referred for CART |
|
9:45 AM
|
E350
|
Refining Local Therapies in Central Nervous System Oncology
Clinical Science Symposium: Redefining the Boundaries of Local Therapy |
Monday, June 2
|
8:00 AM
|
S100A
|
Gynecologic Cancer
Oral Abstract Session: Cuts Both Ways: Surgical Impact in Gynecologic Malignancies |
|
9:00 AM
|
Hall A
|
Genitourinary Cancer – Kidney & Bladder
Poster Session: Intravesical sacituzumab tirumotecan in participants with intermediate-risk non–muscle-invasive bladder cancer: The phase 1/2 TroFuse-027 study |
|
|
9:00 AM
|
Hall A
|
Genitourinary Cancer – Kidney & Bladder
Poster Session: A phase II trial to evaluate clinical efficacy, pharmacodynamics and exploratory analysis of pemetrexed in relation to MLL4 and UTX alteration status in patients with relapsed/refractory metastatic urothelial carcinoma and other solid tumors |
|
|
9:00 AM
|
Hall A
|
Breast Cancer - Metastatic
Poster Session: Integrating dynamic analysis of serial ctDNA testing to enhance diagnostic and prognostic assessments in patients with metastatic breast cancer |
|
9:45 AM
|
S406
|
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Education Session: Where Are We: Liquid Biopsy and ctDNA for Biomarker-Driven Therapies for Cancer Detection and Treatment |
|
11:30 AM
|
S504
|
Sarcoma
Rapid Oral Abstract Session: A clinical and genomic landscape analysis of GI stromal tumors |
connect with us on social
Use #ASCO25 to follow and share insights from the meeting on Twitter, tagging:
- Lurie Cancer Center: @LurieCancer
- Northwestern Medicine: @NorthwesternMed
NORTHWESTERN MEDICINE onCOLOGY
|
The Robert H. Lurie Comprehensive Cancer Center of Northwestern University at Northwestern Memorial Hospital is a global leader in the treatment of a broad range of cancer types due to its dedication to comprehensive clinical oncology research, world-renowned faculty, physicians and oncologists, and its commitment to making breakthroughs in medical, surgical, radiation and interventional oncology. The Lurie Cancer Center is designated by the National Cancer Institute as one of only 57 comprehensive cancer centers in the nation recognized for their scientific leadership, resources and the depth and breadth of their research. In addition, Lurie Cancer Center is a founding member of the National Comprehensive Cancer Network (NCCN) and our physicians actively participate in writing NCCN patient guidelines for each type cancer.
|